Von Eschenbach Nomination Still Stalled After Some Movement On Plan B
This article was originally published in The Gray Sheet
Executive Summary
Senators Hilary Rodham Clinton (D-N.Y.) and Patty Murray (D-Wash.) will maintain their hold on Andrew von Eschenbach's nomination to head FDA, despite what von Eschenbach calls an "important decision" regarding Barr Laboratories' application to offer its Plan B emergency contraceptive over the counter (OTC)
You may also be interested in...
Von Eschenbach nomination on track?
Sens. Hillary Rodham Clinton (D-N.Y.) and Patty Murray (D-Wash.) drop their hold on Acting FDA Commissioner Andrew von Eschenbach's nomination to the permanent post Aug. 24 following the agency's decision to make Barr Pharmaceuticals' Plan B emergency contraceptive available over-the-counter for women age 18 and older (1"The Gray Sheet" Aug. 7, 2006, p. 17). However, at least one Republican is said to be considering a hold in opposition to the Plan B decision, according to a Senate Health, Education, Labor & Pensions Committee staffer. Committee Chair Michael Enzi (R-Wyo.) has not yet scheduled a vote on the nominee, the staffer says. Enzi is reviewing the approval decision and gauging committee members' reactions to it...
Von Eschenbach nomination on track?
Sens. Hillary Rodham Clinton (D-N.Y.) and Patty Murray (D-Wash.) drop their hold on Acting FDA Commissioner Andrew von Eschenbach's nomination to the permanent post Aug. 24 following the agency's decision to make Barr Pharmaceuticals' Plan B emergency contraceptive available over-the-counter for women age 18 and older (1"The Gray Sheet" Aug. 7, 2006, p. 17). However, at least one Republican is said to be considering a hold in opposition to the Plan B decision, according to a Senate Health, Education, Labor & Pensions Committee staffer. Committee Chair Michael Enzi (R-Wyo.) has not yet scheduled a vote on the nominee, the staffer says. Enzi is reviewing the approval decision and gauging committee members' reactions to it...
Von Eschenbach attacked from both sides
Conservatives, including Concerned Women for America and the National Pro-Life Action Center, call for the withdrawal of FDA Acting Commissioner Andrew von Eschenbach's nomination to head the agency in reaction to FDA signals that it might be moving toward approving over-the-counter status for Barr Pharmaceutical's Plan B emergency contraceptive. The firm plans to resubmit its OTC application by the end of the month after an Aug. 8 meeting with the agency. Meanwhile, Sens. Hilary Clinton (D-N.Y.) and Patty Murray (D-Wash.), who support the OTC switch, said July 31 they will maintain their hold on von Eschenbach's nomination until the agency makes a decision (1"The Gray Sheet" Aug. 7, 2006, p. 17)...